| Index | — | P/E | 58.65 | EPS (ttm) | 2.04 | Insider Own | 2.41% | Shs Outstand | 45.50M | Perf Week | 0.96% |
| Market Cap | 5.44B | Forward P/E | 20.57 | EPS next Y | 5.82 | Insider Trans | 0.00% | Shs Float | 44.89M | Perf Month | 14.64% |
| Enterprise Value | 6.39B | PEG | 4.01 | EPS next Q | 1.29 | Short Float | 7.64% | Perf Quarter | 37.86% | ||
| Income | 97.00M | P/S | 4.03 | EPS this Y | 7.47% | Short Ratio | 4.66 | Perf Half Y | 101.91% | ||
| Sales | 1.35B | P/B | 6.50 | EPS next Y | 9.50% | ROA | 4.07% | Short Interest | 3.43M | Perf YTD | 49.28% |
| Book/sh | 18.40 | P/C | 24.41 | EPS next 5Y | 14.62% | ROE | 11.35% | 52W High | 123.77 -3.33% | Perf Year | 142.01% |
| Cash/sh | 4.90 | P/FCF | 18.77 | EPS past 3/5Y | -2.91% 5.75% | ROIC | 8.61% | 52W Low | 49.00 144.18% | Perf 3Y | 40.83% |
| Dividend Est. | — | EV/EBITDA | 24.50 | Sales past 3/5Y | 4.50% 8.92% | Gross Margin | 57.38% | Volatility | 2.33% 2.92% | Perf 5Y | 66.76% |
| Dividend TTM | — | EV/Sales | 4.73 | EPS Y/Y TTM | -37.61% | Oper. Margin | 18.18% | ATR (14) | 3.28 | Perf 10Y | 245.21% |
| Dividend Ex-Date | — | Quick Ratio | 1.92 | Sales Y/Y TTM | 0.30% | Profit Margin | 7.12% | RSI (14) | 63.27 | Recom | 2.43 |
| Dividend Gr. 3/5Y | — | Current Ratio | 3.08 | EPS Q/Q | 3.64% | SMA20 | 2.34% | Beta | 0.63 | Target Price | 130.80 |
| Payout | 0.00% | Debt/Eq | 1.40 | Sales Q/Q | 5.61% | SMA50 | 8.80% | Rel Volume | 0.63 | Prev Close | 119.79 |
| Employees | 3,009 | LT Debt/Eq | 1.40 | Earnings | Nov 05 | SMA200 | 52.16% | Avg Volume | 720.41K | Price | 119.65 |
| IPO Date | May 10, 1991 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 5.87% 3.51% | Net Debt/EBITDA | 3.64 | Volume | 452,863 | Change | -0.12% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-09-26 | Reiterated | Barrington Research | Outperform | $118 → $140 |
| Oct-09-26 | Reiterated | Mizuho | Outperform | $85 → $140 |
| Oct-08-26 | Reiterated | BTIG | Buy | $96 → $130 |
| Sep-17-26 | Upgrade | Citigroup | Neutral → Buy | |
| Sep-03-26 | Reiterated | Raymond James | Outperform | $105 → $125 |
| Aug-21-26 | Reiterated | Robert W. Baird | $96 → $119 | |
| Aug-19-26 | Reiterated | Barrington Research | Outperform | $95 → $118 |
| Aug-07-26 | Reiterated | Raymond James | Outperform | $90 → $105 |
| Aug-07-26 | Reiterated | Robert W. Baird | $88 → $96 | |
| Aug-07-26 | Reiterated | Barrington | Outperform | $89 → $95 |
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2026 3/28/2026 | FY 2025 3/29/2025 | FY 2024 3/31/2024 | FY 2023 3/31/2023 | FY 2022 3/31/2022 | FY 2021 3/31/2021 | FY 2020 3/31/2020 | FY 2019 3/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,351 | 1,334 | 1,361 | 1,309 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 577 | 590 | 582 | 597 | — | — | — | — | — | |
| Gross Profit | 775 | 744 | 779 | 712 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 451 | 442 | 422 | 421 | — | — | — | — | — | |
| Research and Development | 59 | 60 | 69 | 63 | — | — | — | — | — | |
| Other Operating Expense | 20 | 0 | 66 | 63 | — | — | — | — | — | |
| Operating Income | 245 | 241 | 222 | 165 | — | — | — | — | — | |
| Interest Expense | 30 | 29 | 10 | 13 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -84 | -85 | 0 | 0 | — | — | — | — | — | |
| Net Income Before Taxes | 131 | 128 | 212 | 152 | — | — | — | — | — | |
| Income Taxes | 35 | 31 | 44 | 34 | — | — | — | — | — | |
| Consolidated Net Income | 97 | 97 | 168 | 118 | — | — | — | — | — | |
| Net Income From Continuing Operations | 97 | 97 | 168 | 118 | — | — | — | — | — | |
| Net Income | 97 | 97 | 168 | 118 | — | — | — | — | — | |
| EPS (Recurring) | 2.06 | 2.05 | 3.31 | 2.32 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 2.06 | 2.05 | 3.31 | 2.32 | — | — | — | — | — | |
| EPS (Diluted) | 2.04 | 2.05 | 3.31 | 2.29 | — | — | — | — | — | |
| EBITDA | 261 | 268 | 363 | 304 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 58.65 | 26.36 | 19.09 | 37.27 | — | — | — | — | — | |
| Price To Sales Ratio | 3.99 | 1.90 | 2.32 | 3.33 | — | — | — | — | — | |
| Gross Margin | 57.36 | 55.77 | 57.24 | 54.39 | — | — | — | — | — | |
| Operating Margin | 18.13 | 18.07 | 16.31 | 12.61 | — | — | — | — | — | |
| Net Margin | 7.18 | 7.27 | 12.34 | 9.01 | — | — | — | — | — | |
| Shares Outstanding | 45 | 47 | 50 | 51 | — | — | — | — | — | |
| Market Capitalization | 5,384 | 2,540 | 3,160 | 4,353 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| KROLL MARK W | Director | Nov 10 '25 | Buy | 70.56 | 1,400 | 98,784 | 24,757 | Nov 12 |
| Strong Stewart W | President, Global Hospital | Jul 26 '24 | Sale | 91.15 | 4,312 | 393,039 | 18,196 | Jul 29 |
| Lingamneni Anila | EVP, Chief Technology Officer | Jul 12 '24 | Sale | 90.00 | 79 | 7,110 | 21,331 | Jul 15 |
| Lingamneni Anila | EVP, Chief Technology Officer | Jul 11 '24 | Sale | 90.00 | 2,136 | 192,240 | 21,410 | Jul 15 |
| Simon, Christopher | President & CEO | Jun 06 '24 | Option Exercise | 41.64 | 104,516 | 4,352,046 | 433,877 | Jun 07 |
| Basil Michelle L | EVP and General Counsel | May 29 '24 | Sale | 88.08 | 12,990 | 1,144,209 | 31,257 | May 29 |
| Strong Stewart W | President, Global Hospital | May 29 '24 | Sale | 87.53 | 8,857 | 775,253 | 18,196 | May 29 |
| Llorens Josep | EVP, Global Manufacturing | May 20 '24 | Sale | 95.08 | 987 | 93,844 | 21,310 | May 21 |
| Basil Michelle L | EVP and General Counsel | May 20 '24 | Sale | 95.08 | 1,604 | 152,508 | 31,257 | May 21 |
| Strong Stewart W | President, Global Hospital | May 20 '24 | Option Exercise | 56.57 | 2,241 | 126,773 | 20,437 | May 21 |
| Strong Stewart W | President, Global Hospital | May 20 '24 | Sale | 95.11 | 686 | 65,245 | 18,196 | May 21 |
| Basil Michelle L | EVP and General Counsel | May 17 '24 | Sale | 95.00 | 1,073 | 101,935 | 29,352 | May 21 |
| Llorens Josep | EVP, Global Manufacturing | May 17 '24 | Sale | 94.82 | 822 | 77,942 | 16,350 | May 21 |
| Strong Stewart W | President, Global Hospital | May 16 '24 | Option Exercise | 57.60 | 2,410 | 138,816 | 18,018 | May 17 |
| Strong Stewart W | President, Global Hospital | May 16 '24 | Sale | 96.04 | 733 | 70,397 | 15,608 | May 17 |